Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
By N. Nussmeier, A. Whelton, Mark T. Brown, R. Langford, A. Hoeft, J. Parlow, S. Boyce, K. Verburg. New England Journal of Medicine, 2005
1,086 citations recorded by the source corpus.
Subfields: Pathology and Forensic Medicine, Pharmacology, Surgery
View Paper: https://www.semanticscholar.org/paper/bbd6cd190a0b322488d75cbd2da97c2626a4e8f6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Surgery
Citations in the corpus
- ACCF/AHA Practice Guideline 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011, methodology): “The following studies were excluded: (1) nonrandomized trials, (2) duplicate publications, (3) those evaluating the”
- Does Multimodal Analgesia with Acetaminophen, Nonsteroidal Antiinflammatory Drugs, or Selective Cyclooxygenase-2 Inhibitors and Patient-controlled Analgesia Morphine Offer Advantages over Morphine Alone?: Meta-analyses of Randomized Trials (2005, result): “5%) receiving placebo; that difference, however, was not statistically significant.(75) Also, a previous meta-analysis, including a limited number of patients, suggested that postoperative NSAID-related renal dysfunction was clinically unimportant and transient and that NSAIDs, therefore, should not”
- 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesi (2011, background): “Subequently, 2 RCTs, both studying the oral cyclooxygenase-2 nhibitor valdecoxib and its intravenous prodrug, parecoxib, eported a higher incidence of sternal infections in 1 trial nd a significant increase in adverse cardiovascular events in he other (26,27).”